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Abstract
Giant cell arteritis (GCA), or temporal arteritis, is a medium to large vessel vasculitis seen in the elderly. Its presentation varies from fever of unknown origin to cranial ischemic complications including complete vision loss. The
early initiation of steroids is key to preventing complications of GCA. Here we discuss the role of aspirin in the
treatment of GCA, both as an antithrombotic agent and its increasingly utilized anti-inﬂammatory properties. The aim of
this review article is to examine the evidence behind the use of aspirin as an adjunct to steroids for the prevention of
cranial ischemic complications.
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G

iant cell arteritis (GCA) is a form of vasculitis
affecting the medium and large sized vessels.
It is a disease of the older population with an estimated mean age of 701 and has an incidence of 18
cases per 100,000 people in those over 50 years old.2
GCA is more likely to affect females than males with
a female-to-male preponderance of 2e6:1.3e5 The
clinical presentation varies depending on the arteries involved but the classic features of GCA
include headache, scalp tenderness, jaw claudication, and visual impairment which can be insidious
or acute. Constitutional symptoms of fatigue, malaise, low grade fever, anorexia and weight loss
frequently accompany the classic symptoms.6,7
Empiric treatment should be promptly initiated
upon suspicion as GCA is a medical emergency that
can cause irreversible visual loss.3,5,8 Giant cell
arteritis symptoms can be successfully abated with
glucocorticoids but relapses are common and can be
seen during or after steroid taper. The risk of
recurrent vision loss is estimated to be 7% in 3 years,
while the risk of relapse increases to 77% when
steroids are discontinued within the ﬁrst year.9
Extensive and prolonged use of glucocorticoids are
associated with severe side effects including but not

limited to weight gain, mood instability, gastric
bleeding, osteoporosis and adrenal crisis. Steroidsparing agents are therefore required in patients
with frequent relapse or those at high risk of relapse
to avoid these aforementioned side effects. Table 1
lists the commonly prescribed steroid-sparing
agents for giant cell arteritis with their mechanism
of action.
The catastrophic complications of GCA can
extend beyond permanent visual loss to include
cerebrovascular ischemia, scalp necrosis, tongue
infarction, limb ischemia and aortic dissection.10,11
The pathophysiology of these feared complications
stems from arterial inﬂammation with subsequent
stenosis and occlusions, the end result of which is
ischemia.11 Ischemia involving the structures of the
eye give rise to a myriad of visual impairments
ranging from transient visual loss (amaurosis fugax)
to complete visual loss.12
The role of aspirin in the treatment of GCA has
been debated for many years. While it was initially
recommended for use in GCA by The European
League Against Rheumatism (EULAR) and The
British Society for Rheumatology (BSR), more
recently rheumatologists have questioned its role
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Table 1. Mechanism of Action of Glucocorticoid sparing agents for giant cell arteritis.
Drug Class

Mechanism of action

Methotrexate

Inhibition of ATIC leading to intracellular accumulation of AICAR and suppressing inﬂammatory and
immune reactions.
Interleukin-6 receptor inhibitor leading to reduction in cytokine and acute phase reactant production
IL-12 and IL-23 blockers which decreases T helper (Th) 1 and Th 17 cells.
Incorporate into DNA and halts replication

Tocilizumab
Ustekinumab
Azathioprine

given the conﬂicting data available from retrospective studies and concerns about the risk of gastrointestinal bleeding in the elderly.13,14 In 2020
EULAR reversed its initial stance recommending
that antiplatelet therapy in GCA be limited to patients with cardiovascular indications or at very high
risk of ischemic complications. This change in
viewpoint ignited the authors’ curiosity to research
the subject matter.29 We performed a comprehensive literature review of articles evaluating the use of
aspirin in GCA published since 2000. 72 articles
were initially identiﬁed which were scrutinized and
ﬁnally narrowed to 30 articles which were then
reviewed in the writing of this manuscript.
Aspirin, also known as acetylsalicylic acid, irreversibly inactivates cyclooxygenase to suppress the
production of prostaglandins and thromboxane A2.
The blockage of thromboxane A2 formation inhibits
downstream platelet aggregation which in turn
mediates an anti-thrombotic effect that forms the
basis of using aspirin to prevent ischemic events.15
In GCA ischemia occurs as inﬂammation results
in narrowing of the vessel lumen which impedes
forward blood ﬂow. While steroids will rapidly
improve the systemic symptoms of GCA, the inﬂammatory inﬁltrates in the vessel wall take longer
to resolve. There is an increasingly recognized need
to utilize agents that will target the inﬂammatory
process in GCA at a molecular level. Weyand et al.
undertook a prospective study using mice chimeras
that had been engrafted with inﬂamed temporal
arteries to mimic GCA that were then treated with
aspirin or dexamethasone. They found that dexamethasone suppressed transcription of INF-g
by  85% (P ¼ 0.034), whereas aspirin suppressed its
transcription by 90% (P ¼ 0.015). Contrary to that,
dexamethasone
overwhelmingly
suppressed
macrophage/NF-kB production of IL-6 (P ¼ 0.007)
and IL-1b (P ¼ 0.014), whereas the effect of aspirin
was much less pronounced with IL-1b production
continuing at 66% (P ¼ 0.223) and IL-6 production
only reducing to 51% (P ¼ 0.043). They then hypothesized that if inﬂammation in GCA is mediated
through both the NF-kB pathway (via IL-6 and IL1b, which dexamethasone inhibits) and the INF-g
pathway (which aspirin inhibits), then simultaneous

use of the two agents might provide a synergistic
effect that could potentially speed up the clearance
of inﬂammatory inﬁltrates in vessel wall to restore
blood ﬂow and prevent or reduce the severity of
ischemic complications.16 Kaiser and colleagues led
further credence to this theory when they found a
correlation between the expression levels of INF-g
and ischemic complications in GCA.17
Two studies carried out by Nesher and Lee have
been the main catalyst for the adoption of aspirin
use at the initiation of GCA treatment. Lee et al.
retrospectively studied the role of antiplatelets and
anticoagulation in GCA patients. Out of the 143
patients studied 104 had biopsy-proven diagnosis of
GCA. 60.1% of the patients received either antiplatelets or anticoagulants with 16.2% of those patients developing ischemic events compared to the
48.0% ischemic rate in those not treated with antiplatelet nor anticoagulant agents (P < 0.0005). This
data demonstrated the beneﬁt of antiplatelet or
anticoagulant therapy in reducing ischemic events
in GCA patients, notably without an increased risk
of bleeding complications.19 Similarly, Nesher et al.
published a retrospective study of 166 GCA patients
in which they compared cranial ischemic complications (CICs) both at presentation and after 3month follow up period.18 At time of GCA diagnosis, patients who happened to be on aspirin for
cardiovascular indications had a lower CIC rate (8%)
on presentation compared to those not on aspirin
(29%) (p ¼ 0.01) despite their increased baseline risk
of ischemic complications. Likewise, when the same
patients were evaluated at the 3-month mark; CICs
occurred in 3% of patients who were started on
aspirin for GCA compared to 13% of patients in the
group not treated with aspirin (P ¼ 0.02). This
decline in CIC from 13% to 3% would translate into
10 patients needing to be treated to prevent 1 CIC.18
Now, this retrospective study should be interpreted
with caution as it does not carry the weight a Randomized Controlled Trial. Some of the limitations of
the study include the lack of a predeﬁned protocol
and also the potential that a confounding variable
affecting CICs might not have been accounted for
such as cardiovascular modiﬁers like smoking and
statin use that were not included in the evaluation.

Despite its limitation, this effect remains remarkable
especially given the potential risk of permanent
blindness in GCA.
A case series of ﬁve patients was detailed by
Alsolaimani et al. in which all GCA patients
received aspirin in addition to prednisone. Two out
of the ﬁve patients had full neurological recovery
while three had lingering neurological sequelae.20
Souza et al. carried out a randomized control trial of
45 GCA patients treated with aspirin and steroids.
They found aspirin had a protective effect against
relapse (OR 0.02, P ¼ 0.023) after adjusting for age,
gender, and ethnicity, further supporting the protective effect of aspirin as an adjunct to steroids,
although some of the study participants did receive
methotrexate as a steroid-sparing agent.21
The previously-cited studies all supported the use
of aspirin in GCA but more recently authors have
called into question this approach and voiced concerns about the risk of bleeding complications.
Spiera et al. postulated that the main reason for
conﬂicting results when aspirin use in GCA is
evaluated is because the principal cause of ischemic
complications is intimal hyperplasia and not
thrombosis.23 J Narvaez and colleagues undertook a
retrospective analysis of 121 patients diagnosed with
GCA using temporal artery biopsy or through
fulﬁlment of the 1990 ACR classiﬁcation criteria.
They compared patients who were on antiplatelet
therapy (n ¼ 37) prior to diagnosis with continuation
post-diagnosis versus a control arm of patients who
did not receive antiplatelet therapy (n ¼ 84). The
rates of severe ischemic complications, deﬁned as
severe visual manifestations, cerebrovascular accidents, ischemic heart disease and limb claudication,
were 24.3% (9/37) in the intervention group
compared to 29.8% (25/84) with a P value of 0.54.
When the deﬁnition of severe ischemic complication
was expanded to include jaw claudication, the incidence of ischemic events increased to 46.4% in the
intervention and 59.5% in control group (P ¼ 0.187).
This reduction in ischemic events in the antiplatelet
group, while non-signiﬁcant, was noted despite the
increased atherosclerotic risk factors in that group.
There was no signiﬁcant difference between the two
groups in terms of frequency of relapse, percentage
recovery from GCA, or duration of treatment. The
group receiving antiplatelets did appear to beneﬁt
from a lower cumulative dose of steroids.22
Berger and colleagues hypothesized that if platelet
aggregation was the root cause of ischemia in GCA
then an association should be seen between
ischemic events in GCA with higher platelet size
and count or platelet inhibition by aspirin. They
carried out a retrospective analysis of 85 patients
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with GCA diagnosed through the 1990 ACR classiﬁcation criteria or positive temporal artery biopsy
with GCA evidence of AION or large-vessel vasculitis on PET scan. Out of the 85 patients, 26% (22/85)
were treated with aspirin with a 68% incidence of
ischemic events and a 32% incidence of severe
ischemic events in the aspirin-treated group. Using
multiple regression analysis they found that use of
aspirin was associated with non-signiﬁcant
decreased risk of both ischemic and severe ischemic
events with respective odds ratio of 0.87 (95% CI
0.25-3.08 P ¼ 0.83) and 0.86 (95% CI 0.252.96 P ¼ 0.81) Thrombocytosis and mean platelet
volume (MPV) were equally associated with a nonsigniﬁcant increased risk of both ischemic and severe ischemic events.24 Gonzalez-Gay et al., in 2005
also noted no difference in platelet counts between
those with and without severe ischemic events using
the largest published GCA cohort of 240 patients.25
Thus, at a pathological level available literature has
not been able to demonstrate with statistical significance that it is indeed the antiplatelet property of
aspirin which reduces ischemic complications. A
systemic review by Fraser et al. evaluating all
treatments in GCA did recommend the use of
aspirin in preventing ischemic complications of
GCA basing their decisions on the statistically signiﬁcant results of Nesher and Lee.26 One can hypothesize that Lee et al. results was ampliﬁed
because a high percentage of the cohort were
treated with aspirin.19
Cranial ischemic complications (CICs) are usually
seen at presentation but can present later during
ongoing steroid therapy, posing treatment challenges. While it is not possible to prevent the CICs
that are present at the time of diagnosis, it is
possible to prevent the CICs that occur later. Pipitone et al. found that patients at increased risk of
vision loss were more likely to be of older age, have
lower ESR values, and fewer systemic symptoms.27
In the same vein, Nesher et al. found that male
gender and occurrence of transient cerebroophthalmic ischemic episodes (COIEs) were positive risk factors and that the presence of CIC at
presentation increases the risk of subsequent
CICs.19 With that ﬁnding in mind, GCA patients at
high risk of CICs should have early aggressive
treatment, while those at low risk of CICs may be
started on less aggressive regimens with the prospect of avoiding steroid-related adverse events.18
Treatment of GCA is not without risk, the most
concerning one being gastrointestinal (GI) bleeding
especially when high dose steroids are being utilized. As physicians living by the Hippocratic Oath
of “do no harm”, it is imperative to perform a risk-
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Table 2. Compares effect of aspirin on reducing ischemic complications of Gca.
Study design

N

Population/inclusion
criteria

Treatment groups OR
intervention

Control Group

Primary end point

Outcome treatment
group

Nesher et al.

Retrospective

166

GCA on temporal artery biopsy or 1990
ACR criteria

Prednisone and ASA

Prednisone

CIC both at presentation and during follow
up

Lee et al.

Retrospective

143

GCA diagnosed by
TAB or ACR GCA
criteria (1980e2004)

Prednisone plus ASA
or clopidogrel or
warfarin

Prednisone

Occurrence of any
ischemic events.

Narvaez

Retrospective

121

GCA diagnosed by
TAB or ARC GCA
criteria 1990

Prednisone plus ASA,
clopidogrel or
ticlopidine

Prednisone

Occurrence of severe
ischemic complications

Berger et al.

Retrospective

85

GCA diagnosed by
ACR GCR criteria 1990
or positive TAB

ASA with
glucocorticoids

glucocorticoids

Association of ischemic
events with ASA use

Souza et al.

Retrospective cohort

45

ACR criteria diagnosed
GCA

ASA with
glucocorticoids

glucocorticoids

Weyand et al.

Chimeric mouse
model (Experimental)

Mice chimera engrafted with inﬂamed
temporal arteries

Injections of ASA
100 mg/kg vs indomethacin vs dexamethasone 500 mg/kg
for 3 weeks

Injections of saline

Demographic features,
clinical manifestations,
treatments and outcomes of GCA in Brazilian cohort
Transcription of IL-1b
and NF-kB

ASA use reduced both:
CIC at presentation
(OR 0.3 p ¼ 0.06) and
CICs follow up (OR
0.2 P ¼ 0.02)
Ischemic event rate
16.2% vs 48%
(p < 0.005). Within
intervention subgroups: ASA
(OR ¼ 0.18 P < 0.0005);
warfarin (OR ¼ 0.17
p < 0.04)
Severe ischemic complications in antiplatelet group (24.3 vs 29.8%
P ¼ 0.54)
ASA reduced risk of
ischemic events OR
0.87 (P ¼ 0.83) and severe ischemic events
OR 0.86 (P ¼ 0.81)
ASA use associated
with lower relapse
when adjusted for age,
gender
Suppression of INF-g
transcription by ASA
90% (P ¼ 0.015) vs
Dexamethasone 85%
(p ¼ 0.034)
IL-1b production
continued with ASA at
66% (P ¼ 0.223) vs
profound suppression
by dexamethasone
(P ¼ 0.014).
IL-6 production
reduced by ASA to
51% (P ¼ 0.043) vs
profound suppression
by dexamethasone
(P ¼ 0.007)

N- Patient Number, CIC-cranial ischemic complications, TAB- Temporal artery biopsy, GCA-giant cell arteritis, ACR- American college of rheumatology, ASA aspirin.
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beneﬁt analysis to identify patients mostly like to
beneﬁt and on the other hand recognize patients at
increased risk of adverse events. Unlike rheumatoid
arthritis where disease speciﬁc scores have been
developed to identify increased cardiovascular risk,
no GCA speciﬁc scores have been developed, thus,
we recommend using the validated Atherosclerotic
Cardiovascular Disease (ASCVD) score of the
American College of Cardiology/American Heart
Association (ACC/AHA) to identify patients at
increased risk of cardiovascular events. Conversely
the, the aspirin cardiovascular/gastrointestinal risk
calculator is a useful tool to aid physicians outside of
clinical acumen to identify patients at increased risk
of GI bleeding.28
More recently in the ﬁeld of GCA; Tocilizumab,
the IL-6 inhibitor has proven its efﬁcacy in the
treatment of GCA especially in its role as a steroid
sparing agent. The FDA approval came after two
landmark trials. In the ﬁrst trial by Villiger et al.;
primary end point of complete remission at 12
weeks was achieved by 85% of the Tocilizumab
compared to 40% of the placebo. This risk difference
was sustained when relapse free survival at 52
weeks was seen in 85% of the Tocilizumab group
compared to the 20% of the placebo group.29 The
second trial by Stone et al. showed similar results
with sustained remission at 52 weeks in 56% of patients on weekly Tocilizumab, 53% in alternate
weekly dosing of Tocilizumab, 14% in placebo
group on 26-week steroid taper and 18% in placebo
group on 52-week steroid taper.30 It is interesting to
point out that all patients enrolled in the ﬁrst trial
received aspirin 100 mg daily and similarly patients
in the second trial all received either low dose
aspirin or Clopidogrel.

1. Conclusion
The literature regarding aspirin use in GCA while
initially promising has produced conﬂicting results.
Currently, the American College of Rheumatology
(ACR) recommends use of aspirin in GCA with
critical or ﬂow limiting vertebral or carotid disease
while the EULAR only recommends aspirin use
when patient has additional antiplatelet requirements whilst advocating individual consideration in GCA with high ischemic risk.31,32
Prospective randomized control trials are needed to
fully evaluate the efﬁcacy of aspirin in GCA. We
recommend a case-by-case approach weighing
beneﬁts against risks using validated scoring systems such as ASCVD and aspirin cardiovascular/
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gastrointestinal risk calculator. For GCA patients at
high risk of CICs and low bleeding risk, we
recommend considering adding aspirin to the
treatment regimen. But if the risk of ischemic
complication is low with a signiﬁcant bleeding risk,
then aspirin should be avoided (see Table 2).
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